MarginsXMarginsX
Home › Markets › Health Care › GHRS

GH Research PLC (GHRS)

GHRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$18.75
-1.83% on the day
Market cap
$1.3B
Small cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerGHRS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIreland
IPO year2021
SEC CIK0001855129
SEC industry codePharmaceutical Preparations
Incorporated inIreland

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
67.9 months
$246.3M cash at December 31, 2025
Share count, 1 year
+19.2%
2024-12-31 to 2025-12-31 · +19.2% over 3 years
Going-concern doubt
No
20-F filed March 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-05
Cash and burn$246.3M cash; operating cash flow -$10.9M a quarter.Report 2025-12-31
Shares outstanding62,029,395 (2025-12-31); 52,028,145 a year earlier; 52,020,849 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers, Dublin, IrelandPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$48.3M-$43.6M$246.3M$0Needs four quarters20-F 2026-03-05
FY 2024
2024-12-31
Not filed-$39.0M-$42.3M$100.8M$0Needs four quarters20-F 2026-03-05
FY 2023
2023-12-31
Not filed-$35.6M-$33.3M$78.4M$0Needs four quarters20-F 2026-03-05
FY 2022
2022-12-31
Not filed-$22.5M-$26.2M$166.0M$0Needs four quarters20-F/A 2025-07-29
FY 2021
2021-12-31
Not filed-$9.2M-$15.3M$276.8M$0Needs four quarters20-F 2024-03-07
FY 2020
2020-12-31
Not filed-$446K-$330K$5.9MNo debt tagsNeeds four quarters20-F/A 2023-06-02
FY 2019
2019-12-31
Not filed-$310K-$289K$498KNo debt tagsNeeds four quarters20-F 2022-03-28

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentF-32026-05-14
Latest annual report20-F2026-03-05
Latest quarterly / interim6-K2026-11-13

Source: SEC EDGAR submissions feed, 203 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.6%
1 month+1.3%
3 months-32.2%
Year to date+50.4%
1 year+39.2%
From 52-week high-37.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B
MNKDMannKind Corporation$3.96-4.24%$1.3B
INVAInnoviva Inc.$18.49-2.84%$1.3B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier